Treatment with the TYK2 inhibitor deucravacitinib improved disease activity, joint and skin symptoms, and quality of life among people with active psoriatic arthritis participating in the POETYK…

Deucravacitinib is an oral immunomodulatory drug marketed under the brand name Sotyktu. Pharmacologically, Deucravacitinib is a selective tyrosine kinase 2 inhibitor, commonly called a TYK2 inhibitor.

A recent breakthrough in the treatment of Systemic Lupus Erythematosus (SLE) has emerged from the design of two robust clinical trials investigating the efficacy of Deucravacitinib, an innovative oral medication. As a selective allosteric inhibitor of the TYK2 enzyme, Deucravacitinib targets specific pathways implicated in the autoimmune processes of SLE, offering new hope for patients battling this complex disease. The pioneering work conducted by a team of researchers led by C.

Video Abstract

Like last year, 2026 appears poised to herald the arrival of multiple mega-blockbusters—albeit on an even grander scale than 2025’s plenty-respectable slate of major rollouts.According to Evaluate’s…

Linda Stein Gold, MD, describes results from the LATITUDE Atlas study, which compared zasocitinib with deucravacitinib head-to-head for psoriasis.

In this interview with Milaan Shah, MD, the expert consensus panel reviewing deucravacitinib’s safety and efficacy for psoriasis is discussed.

Takeda reports that its investigational oral therapy Zasocitinib achieved markedly stronger outcomes than deucravacitinib in a head-to-head Phase 3 trial in adults with moderate to severe plaque psori...

Deucravacitinib treatment elicited higher response rates for SRI-4 and other end points compared with placebo, with an acceptable safety profile, in adult patients with active SLE.